Accretion Pharmaceuticals IPO

Accretion Pharmaceuticals Limited, founded in 2012, is a pharmaceutical manufacturer based in Sanand, Ahmedabad, Gujarat. The company produces and markets a diverse range of healthcare products, including tablets, capsules, oral liquids, oral powders, and external preparations such as ointments, creams, gels, lotions, and medicated shampoos. It also provides contract manufacturing services to other pharmaceutical entities. With a workforce of 83 employees as of January 2025, including four Executive Directors, Accretion operates with a strong emphasis on quality and compliance.

The company’s product portfolio spans multiple therapeutic categories such as antibiotics, cardiovascular drugs, pain management, gastrointestinal treatments, and pediatric care. It also offers Ayurvedic and herbal products targeting immunity, digestion, and general wellness. Accretion has expanded its reach internationally, with a presence in over 20 countries across Africa, Southeast Asia, and the Middle East, reflecting its growing global footprint in the pharmaceutical sector.

Accretion Pharmaceuticals IPO Strengths

• Accretion Pharmaceuticals manufactures a wide range of pharmaceutical products, including tablets, capsules, oral liquids, external preparations, and oral powders, catering to multiple therapeutic segments and market needs.
• The company exports to over 30 countries, demonstrating strong international reach and diversified revenue streams beyond the domestic market.
• Its manufacturing plants are certified to global standards (WHO-cGMP and GLP), ensuring high product quality, regulatory compliance, and credibility with both domestic and international clients.
• The company has shown consistent year-on-year growth, expanding its team to 400+ professionals and establishing itself as a conglomerate of four robust companies.
• Accretion operates across pharmaceuticals, nutraceuticals, and Ayurveda, allowing it to serve a broader customer base and tap into multiple high-growth healthcare segments.
• State-of-the-art, scalable facilities and advanced technology enable efficient production, cost control, and the ability to meet large-scale orders.

Accretion Pharmaceuticals IPO Risks

• The pharmaceutical sector faces strict regulatory scrutiny in both domestic and export markets. Any failure to comply with evolving quality, safety, or documentation standards could result in penalties, product recalls, or export bans.
• Instances of substandard or spurious drugs have damaged the reputation of Indian pharma companies in the past. Any quality lapses could lead to regulatory action, loss of customer trust, or legal liabilities.
• Like many Indian pharma firms, Accretion may rely on imported Active Pharmaceutical Ingredients (APIs). Disruptions in global supply chains or price spikes can impact production and profitability.
• The generic drug market is highly competitive, with intense pricing pressures both in India and abroad. This can squeeze margins, especially if the company is unable to differentiate its products or control costs.
• India’s pharmaceutical regulatory system is fragmented, with uneven enforcement and lack of uniformity across states. This can result in operational uncertainties and compliance challenges.
• The Indian pharma industry has faced scandals involving spurious medicines and regulatory failures. Any association with such issues, even indirectly, could harm Accretion’s reputation and lead to stricter oversight or legal action.